JP2006514046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514046A5 JP2006514046A5 JP2004565151A JP2004565151A JP2006514046A5 JP 2006514046 A5 JP2006514046 A5 JP 2006514046A5 JP 2004565151 A JP2004565151 A JP 2004565151A JP 2004565151 A JP2004565151 A JP 2004565151A JP 2006514046 A5 JP2006514046 A5 JP 2006514046A5
- Authority
- JP
- Japan
- Prior art keywords
- dhxrie
- block copolymer
- formulation
- oac
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 19
- 229920001400 block copolymer Polymers 0.000 claims 14
- 238000009472 formulation Methods 0.000 claims 13
- 239000003093 cationic surfactant Substances 0.000 claims 9
- -1 polyoxyethylene Polymers 0.000 claims 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 8
- 229920001451 polypropylene glycol Polymers 0.000 claims 8
- 230000002209 hydrophobic effect Effects 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 2
- 238000011166 aliquoting Methods 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 229960000502 poloxamer Drugs 0.000 claims 2
- 239000011148 porous material Substances 0.000 claims 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 1
- MVWTWNIDSWLQQC-UHFFFAOYSA-M acetyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)C(C)=O MVWTWNIDSWLQQC-UHFFFAOYSA-M 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- 229960002798 cetrimide Drugs 0.000 claims 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43530302P | 2002-12-23 | 2002-12-23 | |
| US60/435,303 | 2002-12-23 | ||
| PCT/US2003/038119 WO2004060363A1 (en) | 2002-12-23 | 2003-12-02 | Method for producing sterile polynucleotide based medicaments |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006514046A JP2006514046A (ja) | 2006-04-27 |
| JP2006514046A5 true JP2006514046A5 (enExample) | 2007-09-20 |
| JP5390059B2 JP5390059B2 (ja) | 2014-01-15 |
Family
ID=32713040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004565151A Expired - Fee Related JP5390059B2 (ja) | 2002-12-23 | 2003-12-02 | 無菌ポリヌクレオチド系薬剤の製造方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7381422B2 (enExample) |
| EP (1) | EP1581201A4 (enExample) |
| JP (1) | JP5390059B2 (enExample) |
| AU (1) | AU2003293196A1 (enExample) |
| CA (1) | CA2508281C (enExample) |
| WO (1) | WO2004060363A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105574B1 (en) | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| ATE397942T1 (de) * | 1999-03-26 | 2008-07-15 | Vical Inc | Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen |
| AU2003278776A1 (en) * | 2002-09-10 | 2004-04-30 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection |
| AU2003293195A1 (en) * | 2002-12-23 | 2004-07-29 | Vical Incorporated | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
| WO2004060363A1 (en) | 2002-12-23 | 2004-07-22 | Vical Incorporated | Method for producing sterile polynucleotide based medicaments |
| US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
| AU2005248361B2 (en) * | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
| US20060134221A1 (en) * | 2004-12-03 | 2006-06-22 | Vical Incorporated | Methods for producing block copolymer/amphiphilic particles |
| WO2008148057A2 (en) * | 2007-05-23 | 2008-12-04 | Vical Incorporated | Cationic lipids compositions and methods for enhancing immune responses to vaccines |
| US20140206753A1 (en) | 2011-06-08 | 2014-07-24 | Shire Human Genetic Therapies, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US565611A (en) * | 1896-08-11 | Vehicle-wheel tire | ||
| US5674911A (en) | 1987-02-20 | 1997-10-07 | Cytrx Corporation | Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use |
| US5567859A (en) | 1991-03-19 | 1996-10-22 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| US5811088A (en) * | 1987-02-20 | 1998-09-22 | Emory University | Antiinfective compounds and methods of use |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| DE68916439T2 (de) | 1988-10-05 | 1994-10-20 | Vestar Inc | Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens. |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
| US20030186913A1 (en) | 1990-03-21 | 2003-10-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
| US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5709879A (en) | 1990-06-29 | 1998-01-20 | Chiron Corporation | Vaccine compositions containing liposomes |
| US5696298A (en) | 1991-03-19 | 1997-12-09 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| WO1992016484A1 (en) | 1991-03-19 | 1992-10-01 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| US6933286B2 (en) * | 1991-03-19 | 2005-08-23 | R. Martin Emanuele | Therapeutic delivery compositions and methods of use thereof |
| US7105574B1 (en) | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| US5994314A (en) * | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
| AU697373B2 (en) | 1994-07-29 | 1998-10-01 | Pioneer Hi-Bred International, Inc. | Transgenic cereal plants |
| EP1181937A3 (en) * | 1994-08-09 | 2004-02-04 | Cytrx Corporation | Novel vaccine adjuvant and vaccine |
| US5656611A (en) | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
| US6353055B1 (en) | 1994-11-18 | 2002-03-05 | Supratek Pharma Inc. | Polynucleotide compositions |
| US6359054B1 (en) | 1994-11-18 | 2002-03-19 | Supratek Pharma Inc. | Polynucleotide compositions for intramuscular administration |
| US5641665A (en) | 1994-11-28 | 1997-06-24 | Vical Incorporated | Plasmids suitable for IL-2 expression |
| AU707734B2 (en) | 1995-06-07 | 1999-07-15 | Regents Of The University Of California, The | Stabilization of polynucleotide complexes |
| WO1997006809A1 (en) | 1995-08-21 | 1997-02-27 | Cytrx Corporation | Compositions and methods for growth promotion |
| EP0863749A2 (en) | 1995-11-30 | 1998-09-16 | Vical Incorporated | Complex cationic lipids |
| JP2000506865A (ja) * | 1996-03-14 | 2000-06-06 | ジ イミューン リスポンス コーポレイション | インターフェロンをコードする遺伝子の標的を定めた送達 |
| US5994317A (en) | 1996-04-09 | 1999-11-30 | Vical Incorporated | Quaternary cytofectins |
| DE69732029T2 (de) | 1996-04-26 | 2006-02-23 | Merck & Co., Inc. | Dna enthaltende impfstoffen |
| US20010007771A1 (en) | 1996-05-29 | 2001-07-12 | Sean M. Sullivan | Cationic polymers and lipids for the delivery of nucleic acids |
| US6218112B1 (en) * | 1996-12-23 | 2001-04-17 | Cobra Therapeutics Limited | Optimization of gene delivery and gene delivery system |
| CA2306733A1 (en) | 1997-10-28 | 1999-05-06 | American Home Products Corporation | Compositions and methods for delivery of genetic material |
| AU2868099A (en) * | 1998-02-13 | 1999-08-30 | Selective Genetics, Inc. | Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby |
| CN100471522C (zh) | 1998-03-13 | 2009-03-25 | 惠氏 | 聚核苷酸组合物及其制备方法与用途 |
| WO1999061032A1 (en) | 1998-05-25 | 1999-12-02 | Nippon Shinyaku Co., Ltd. | Process for producing composite preparation containing nucleic acid |
| ATE355856T1 (de) | 1998-07-30 | 2007-03-15 | Point Biomedical Corp | Neuer wirkstoffträger für die gefriertrocknung von wässrigen suspensionen von mikropartikeln |
| US6251599B1 (en) | 1998-11-06 | 2001-06-26 | Selective Genetics, Inc. | Stabilized nucleic acid compositions and methods of preparation and use thereof |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| ATE397942T1 (de) | 1999-03-26 | 2008-07-15 | Vical Inc | Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen |
| ES2260070T3 (es) | 1999-11-19 | 2006-11-01 | Mgi Pharma Biologics, Inc. | Metodo en flujo continuo para preparar microparticulas. |
| ES2167189B1 (es) * | 1999-12-17 | 2003-04-01 | Lipotec Sa | Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos |
| AU2001241958A1 (en) | 2000-03-03 | 2001-09-17 | Valentis, Inc. | Improved poloxamer and poloxamine compositions for nucleic acid delivery |
| CA2407074A1 (en) | 2000-04-21 | 2001-11-01 | Jukka Hartikka | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
| WO2002000844A2 (en) * | 2000-06-23 | 2002-01-03 | Merck & Co., Inc. | Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use |
| US6747690B2 (en) | 2000-07-11 | 2004-06-08 | Phase One A/S | Digital camera with integrated accelerometers |
| AU2002231336B2 (en) | 2000-12-27 | 2007-06-28 | Surefire Medical, Inc. D/B/A Trisalus Life Sciences | Immunomodulatory polynucleotides and methods of using the same |
| US20030129242A1 (en) * | 2002-01-04 | 2003-07-10 | Bosch H. William | Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| AU2003278776A1 (en) | 2002-09-10 | 2004-04-30 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection |
| WO2004060363A1 (en) | 2002-12-23 | 2004-07-22 | Vical Incorporated | Method for producing sterile polynucleotide based medicaments |
| AU2003293195A1 (en) | 2002-12-23 | 2004-07-29 | Vical Incorporated | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
| DK2311848T3 (da) | 2002-12-23 | 2013-10-14 | Vical Inc | Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion |
| US8080642B2 (en) | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
| AU2005248361B2 (en) | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
| US20060134221A1 (en) | 2004-12-03 | 2006-06-22 | Vical Incorporated | Methods for producing block copolymer/amphiphilic particles |
-
2003
- 2003-12-02 WO PCT/US2003/038119 patent/WO2004060363A1/en not_active Ceased
- 2003-12-02 CA CA2508281A patent/CA2508281C/en not_active Expired - Fee Related
- 2003-12-02 JP JP2004565151A patent/JP5390059B2/ja not_active Expired - Fee Related
- 2003-12-02 AU AU2003293196A patent/AU2003293196A1/en not_active Abandoned
- 2003-12-02 US US10/725,015 patent/US7381422B2/en not_active Expired - Fee Related
- 2003-12-02 EP EP03790187A patent/EP1581201A4/en not_active Withdrawn
-
2008
- 2008-04-25 US US12/109,944 patent/US8435557B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006514046A5 (enExample) | ||
| JP2009527505A5 (enExample) | ||
| Verweij et al. | In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries | |
| EP2546246A3 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
| WO2004089239A2 (en) | Topical anthelmintic veterinary formulations | |
| CN113115785B (zh) | 抗微生物化合物、纳米棒和纳米虫 | |
| EP3395876A1 (en) | Novel nanoparticles | |
| JP2011219495A5 (enExample) | ||
| JP2009502743A5 (enExample) | ||
| JP2006182786A5 (enExample) | ||
| CN103356622A (zh) | 治疗用组合物及其用途 | |
| RU2003131879A (ru) | Антагонисты ccr5, полезные для лечения спид | |
| JP2013542981A5 (enExample) | ||
| JP2002532395A (ja) | 農薬水性懸濁液濃縮物 | |
| CA2508281A1 (en) | Method for producing sterile polynucleotide based medicaments | |
| CN1240437C (zh) | 口服的自乳化的吡喃酮蛋白酶抑制剂制剂 | |
| JP2004519067A5 (enExample) | ||
| KR20100014632A (ko) | 플루오로메토론을 함유하는 현탁형 점안제 | |
| EP1327453B1 (en) | Stable taurolidine electrolyte solutions | |
| WO2010145523A1 (zh) | 具有抗hcv活性的化合物及其用途 | |
| US20230332246A1 (en) | Methods for characterizing biological samples | |
| JP2014513749A5 (enExample) | ||
| JP2005535644A5 (enExample) | ||
| WO2003018690A1 (en) | Composition containing fine particles for supporting biologically active substance thereon or having the same supported thereon and method for preparing these | |
| CN1210028C (zh) | 水性液体制剂 |